NRC FORM 313
(10-87)
10 CFR 30, 32, 33, 34, 35 and 40

# APPLICATION FOR MATERIAL LICENSE

U.S. NUCLEAR REGULATORY COMMISSION
APPROVED BY OMB
3150-0120
Expires: 6-30-90

**INSTRUCTIONS:** SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

**APPLICATIONS FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:**

U.S. NUCLEAR REGULATORY COMMISSION
DIVISION OF FUEL CYCLE AND MATERIAL SAFETY, NMSS
WASHINGTON, DC 20555

**ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS. IF YOU ARE LOCATED IN:**

**CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:**

U.S. NUCLEAR REGULATORY COMMISSION, REGION I
NUCLEAR MATERIALS SAFETY SECTION B
475 ALLENDALE ROAD
KING OF PRUSSIA, PA 19406

**ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO:**

U.S. NUCLEAR REGULATORY COMMISSION, REGION II
NUCEAR MATERIALS SAFETY SECTION
101 MARIETTA STREET, SUITE 2900
ATLANTA, GA 30323

**IF YOU ARE LOCATED IN:**

**ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:**

U.S. NUCLEAR REGULATORY COMMISSION, REGION III
MATERIALS LICENSING SECTION
799 ROOSEVELT ROAD
GLEN ELLYN, IL 60137

**ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, SOUTH DAKOTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO:**

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
MATERIAL RADIATION PROTECTION SECTION
611 RYAN PLAZA DRIVE, SUITE 1000
ARLINGTON, TX 76011

**ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:**

U.S. NUCLEAR REGULATORY COMMISSION, REGION V
NUCLEAR MATERIALS SAFETY SECTION
1450 MARIA LANE, SUITE 210
WALNUT CREEK, CA 94596

**PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.**

1. THIS IS AN APPLICATION FOR *(Check appropriate item)*

- [ ] A. NEW LICENSE
- [ ] B. AMENDMENT TO LICENSE NUMBER _____
- [X] C. RENEWAL OF LICENSE NUMBER 08-01728-01

2. NAME AND MAILING ADDRESS OF APPLICANT *(Include Zip Code)*

Providence Hospital
Department of Pathology
1150 Varnum Street, N.E.
Washington, D.C. 20017

3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED.

Providence Hospital
Department of Pathology
1150 Varnum Street, N.E.
Washington, D.C. 20017

| 4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION | TELEPHONE NUMBER |
|---|---|
| Carlos R. Matta, M.D. | (202) 269-7180 |

SUBMIT ITEMS 5 THROUGH 11 ON 8½ x 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

| | |
|---|---|
| 5. RADIOACTIVE MATERIAL<br>a. Element and mass number, b. chemical and/or physical form, and c. maximum amount which will be possessed at any one time. | 6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED. |
| 7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE. | 8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS. |
| 9. FACILITIES AND EQUIPMENT. | 10. RADIATION SAFETY PROGRAM. |
| 11. WASTE MANAGEMENT. | 12. LICENSEE FEES *(See 10 CFR 170 and Section 170.31)*<br>FEE CATEGORY 7A<br>AMOUNT ENCLOSED $ 350.00 |

13. CERTIFICATION. *(Must be completed by applicant)* THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN, IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

| SIGNATURE–CERTIFYING OFFICER | TYPED/PRINTED NAME | TITLE | DATE |
|---|---|---|---|
| Sister Catherine Norton | Sister Catherine Norton | President | 9/27/88 |

9003070247 890408
REG1 LIC30
08-01728-01 PDR

**FOR NRC USE ONLY**

| TYPE OF FEE | FEE LOG | FEE CATEGORY | COMMENTS | APPROVED BY |
|---|---|---|---|---|
| Ren | Oct 20 I | 7C | | D. Kimberly |
| AMOUNT RECEIVED | CHECK NUMBER | | | DATE |
| $350/230 | 326832/328346 | | 109682 | 11/8/88 |

SUPPLEMENTARY PAGE - ANSWERS TO ITEMS 5 THROUGH 11

Item 5: See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

Item 6: See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

Item 7: 1. See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

2. See ATT. No. 2 - Preceptor Statement dated September 26, 1988, to authorize the use of Xennon 133 for Blood flow and pulmonary function studies by Carlos R. Matta, M.D.

Item 8: See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

Item 9: See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

Item 10: See ATT. No. 1 - Amendment No. 36 - dated July 15, 1988.

Item 11: See ATT No. 1 - Amendment No. 36 - dated July 15, 1988.

NRC Form 370
(5-84)

ATT M 1 U.S. NUCLEAR REGULATORY COMMISSIO



# MATERIALS LICENSE

Amendment No. 36

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee | |
|---|---|
| 1. Providence Hospital | In accordance with application dated May 27, 1988, 3. License number 08-01728-01 is amended in its entirety to read as follows: |
| 2. 1150 Varnum Street, N.E.<br>Washington, DC 20017 | 4. Expiration date October 31, 1988 |
| | 5. Docket or Reference No. 030-01316 |

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
|---|---|---|
| A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. As necessary for uses authorized in Subitem 9.A. |
| B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. 2 curies of each byproduct material authorized in Subitem 6.B. |
| C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35 | C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35 | C. As necessary for uses authorized in Subitem 9.C. |
| D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35 | D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35 | D. As necessary for uses authorized in Subitem 9.D. |
| E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31 | E. Prepackaged kits | E. 3 millicuries of each byproduct material authorized in Subitem 6.E. |
| F. Strontium 90 | F. Sealed in an ophthalmic applicator (ICN Pharmaceuticals Model 75143) | F. 50 millicuries |
| G. Xenon 133 | G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA | G. 100 millicuries |

8805150088
4pp

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 08-01728-01

Docket or Reference number: 030-01316

Amendment No. 36

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. In vitro studies.
F. For treatment of superficial eye conditions.
G. Blood flow and pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at Providence Hospital, 1150 Varnum Street, N.E., Washington, D.C.

11. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

| | |
|---|---|
| Christian O. Alele, M.D. | Groups I, II, III, IV, and V<br>In vitro studies<br>Xenon 133 |
| Carlos R. Matta, M.D. | Groups I, II, III, IV, and V<br>In vitro studies |
| John R. Moretti, M.D. | Strontium 90 for treatment of superficial eye conditions |
| John R. Fox, M.D. | In vitro studies |
| Michael Brancaccio, M.D. | In vitro studies |

12. Radiation Safety Officer: Carlos R. Matta, M.D.

13. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders or detector cells by the licensee.

14. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

(14. continued) CONDITIONS

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

15. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

A. Has the prior written permission of the hospital's Administrator and Radiation Safety Committee, and

B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

C. Performs only those procedures which the physician is specifically authorized to perform pursuant to a license issued by the Nuclear Regulatory Commission.

The licensee shall maintain for inspection by the Commission copies of the written permission specified in A. above and of the license(s) specified in B. and C. above for a period of 5 years from the date permission is granted under A. above.

16. The licensee may use the Calicheck device for doing linearity tests of its dose calibrator provided it follows the procedures in the Calcorp, Inc., Manual dated March 2, 1982.

17. Patients containing Iodine-131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

18. A(1) Any sealed sources or detector cells specified in Item 7.F. shall be tested for leakage and/or contamination at intervals not to exceed 6 months. Any source or detector cell received from another person which is not accompanied by a certificate indicating that a test was performed within 6 months before the transfer shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source or detector cell is exempt from such leak tests when the source or detector cell contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. Any sealed source or detector cell in storage and not being used need not be tested. When the source or detector cell is removed from storage for use or transfer to another person, it shall be tested before use or transfer.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 08-01728-01

Docket or Reference number: 030-01316

Amendment No. 36

(18. continued) CONDITIONS

C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source or detector cell shall be removed from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendaled Road, King of Prussia, Pennsylvania 19406. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated July 27, 1983 including ALARA Program
B. Letter dated July 26, 1983
C. Letter dated September 20, 1983
D. Letter dated January 22, 1987
E. Letter dated March 19, 1987
F. Letter dated May 27, 1988

For the U.S. Nuclear Regulatory Commission

Date 15 JUL 1988

By _____
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

ATT No. 2

Supplement B (Continued)

PROPOSED PHYSICIAN USER

Carlos R. Matta, M.D.

## PRECEPTOR STATEMENT (Continued)

### 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

| ISOTOPE<br>A | CONDITIONS DIAGNOSED OR TREATED<br>B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION<br>C | COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)<br>D |
|---|---|---|---|
| P-32 (Soluble) | TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES | | |
| P-32 (Colloidal) | INTRACAVITARY TREATMENT | | |
| I-131 | TREATMENT OF THYROID CARCINOMA | | |
| | TREATMENT OF HYPERTHYROIDISM | | |
| Au-198 | INTRACAVITARY TREATMENT | | |
| Co-60 or Cs-137 | INTERSTITIAL TREATMENT | | |
| | INTRACAVITARY TREATMENT | | |
| I-125 or Ir-192 | INTERSTITIAL TREATMENT | | |
| Co-60 or Co-137 | TELETHERAPY TREATMENT | | |
| Sr-90 | TREATMENT OF EYE DISEASE | | |
| | RADIOPHARMACEUTICAL PREPARATION | | |
| Mo-99/ Tc-99m | GENERATOR | | |
| Sn-113/ In-113m | GENERATOR | | |
| Tc-99m | REAGENT KITS | | |
| Other | | | |

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

DATES OF TRAINING: 8-1-88 to 9-23-88

TOTAL NUMBER OF HOURS: 50

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR: Christian O. Alele, M.D.

b. NAME OF INSTITUTION: Providence Hospital

c. MAILING ADDRESS: 1150 Varnum Street, N.E.

d. CITY: Washington, D.C. 20017

5. MATERIALS LICENSE NUMBER(S): 08-01728-01

6. PRECEPTOR'S SIGNATURE

7. PRECEPTOR'S NAME (Please type or print): Christian O. Alele, M.D.

8. DATE: 9-26-88

OFFICIAL RECORD COPY ML 10

03 OCT 1988

109682

ATT No. 2

Supplement B

# PRECEPTOR STATEMENT

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME

Carlos R. Matta, M.D.

STREET ADDRESS

1150 Varnum Street, N.E.

CITY | STATE | ZIP CODE

Washington, D.C. 20017

**KEY TO COLUMN C**

**PERSONAL PARTICIPATION SHOULD CONSIST OF:**

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

| ISOTOPE A | CONDITIONS DIAGNOSED OR TREATED B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C | COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D |
|---|---|---|---|
| I-131 or I-125 | DIAGNOSIS OF THYROID FUNCTION | | |
| | DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME | | |
| | LIVER FUNCTION STUDIES | | |
| | FAT ABSORPTION STUDIES | | |
| | KIDNEY FUNCTION STUDIES | | |
| | IN VITRO STUDIES | | |
| OTHER | | | |
| I-125 | DETECTION OF THROMBOSIS | | |
| I-131 | THYROID IMAGING | | |
| P-32 | EYE TUMOR LOCALIZATION | | |
| Se-75 | PANCREAS IMAGING | | |
| Yb-169 | CISTERNOGRAPHY | | |
| Xe-133 | BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES | 42 | |
| OTHER | | | |
| Tc-99m | BRAIN IMAGING | | |
| | CARDIAC IMAGING | | |
| | THYROID IMAGING | | |
| | SALIVARY GLAND IMAGING | | |
| | BLOOD POOL IMAGING | | |
| | PLACENTA LOCALIZATION | | |
| | LIVER AND SPLEEN IMAGING | | |
| | LUNG IMAGING | | |
| | BONE IMAGING | | |
| OTHER | | | |

PROVIDENCE
HOSPITAL

Celebrating 125 Years of Caring

November 1, 1988

Ms. Glenda Jackson
License Fee Management Branch
Division of Accounting and Finance
Office of Administration and Resources Management
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555

Dear Ms. Jackson:

Attached is a check for $230.00 - the balance due for our application and license renewal - Materials License 08-01728-01; control number 109682. Please note, our application was forwarded earlier, however, the fee submission was incorrect.

We trust this will satisfy the requirement and our application and renewal will be effected.

Sincerely,

Robert A. Massey
Senior Vice President

RAM:cmt



1150 Varnum Street, N.E., Washington, D.C. 20017 - 202/269-7000
A Daughter of Charity Hospital Serving Metropolitan Washington, D.C. Since 1861

OCT 2 8 1988

Providence Hospital
ATTN: Sister Catherine Norton
President
1150 Varnum Street, N. E.
Washington, D. C. 20017

Gentlemen:

This refers to your application dated September 27, 1988, for renewal of Materials License 08-01728-01.

We received your check for $350. Your application, however, is subject to a renewal fee of $580 as specified in §170.31 (7C) of 10 CFR 170, copy enclosed. Payment of the additional $230 should be made to the U.S. Nuclear Regulatory Commission and mailed to my attention at our Washington, D.C. address.

Your application will be processed by the Region I Licensing staff located at 475 Allendale Road, King of Prussia, Pennsylvania 19406. The additional fee, however, is required prior to issuance of the renewal. When submitting the fee, please refer to CONTROL NUMBER 109682.

Sincerely,

**Signed by:**
**Glenda Jackson**

Glenda Jackson
License Fee Management Branch
Division of Accounting and Finance
Office of Administration and
Resources Management

Enclosure:
10 CFR 170

cc: Region I

DISTRIBUTION:
**Pending Fee File**
ARM/DAF R/F
LFMB R/F (2)
DW/RI/PROVIDENCE

| | | |
|---|---|---|
| OFFICE: | ARM/LFMB | ARM/LFMB |
| SURNAME: | SKimberley:lb | GJackson |
| DATE: | 10/24 /88 | 10/26 /88 |

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 2
FEE CATEGORY: 7C
EXP. DATE: 19881031
FEE COMMENTS: _____

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: PROVIDENCE HOSPITAL
RECEIVED DATE: 881003
DOCKET NO: 3001316
CONTROL NO.: 109682
LICENSE NO.: 08-01728-01
ACTION TYPE: RENEWAL

2. FEE ATTACHED
AMOUNT: $350.00
CHECK NO.: 216832

3. COMMENTS

SIGNED R. J. Brown
DATE 88-10-13

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED / )

1. FEE CATEGORY AND AMOUNT: 2C $350

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT _____
RENEWAL /
LICENSE _____

3. OTHER _____
_____

SIGNED D. Kimberly
DATE 11/8/88